1	Pro/antioxidant	_	JJ	_	_	2	NMOD	_	_
2	status	_	NN	_	_	10	VMOD	_	_
3	and	_	CC	_	_	2	COORD	_	_
4	AP-1	_	NN	_	_	6	NMOD	_	_
5	transcription	_	NN	_	_	6	NMOD	_	_
6	factor	_	NN	_	_	3	CONJ	_	_
7	in	_	IN	_	_	2	NMOD	_	_
8	murine	_	JJ	_	_	9	NMOD	_	_
9	skin	_	NN	_	_	7	PMOD	_	_
10	following	_	VBG	_	_	0	ROOT	_	_
11	topical	_	JJ	_	_	12	NMOD	_	_
12	exposure	_	NN	_	_	10	VMOD	_	_
13	to	_	TO	_	_	12	NMOD	_	_
14	cumene	_	NN	_	_	15	NMOD	_	_
15	hydroperoxide	_	NN	_	_	13	PMOD	_	_
16	.	_	.	_	_	10	P	_	_
		
1	Organic	_	JJ	_	_	2	NMOD	_	_
2	peroxides	_	NNS	_	_	13	VMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	widely	_	RB	_	_	5	VMOD	_	_
5	used	_	VBN	_	_	2	APPO	_	_
6	in	_	IN	_	_	5	VMOD	_	_
7	the	_	DT	_	_	11	NMOD	_	_
8	chemical	_	JJ	_	_	11	NMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	pharmaceutical	_	JJ	_	_	9	CONJ	_	_
11	industries	_	NNS	_	_	6	PMOD	_	_
12	,	_	,	_	_	2	P	_	_
13	can	_	MD	_	_	0	ROOT	_	_
14	act	_	VB	_	_	13	VC	_	_
15	as	_	IN	_	_	14	VMOD	_	_
16	skin	_	NN	_	_	18	NMOD	_	_
17	tumor	_	NN	_	_	18	NMOD	_	_
18	promoters	_	NNS	_	_	15	PMOD	_	_
19	and	_	CC	_	_	14	COORD	_	_
20	cause	_	VB	_	_	19	CONJ	_	_
21	epidermal	_	JJ	_	_	22	NMOD	_	_
22	hyperplasia	_	NN	_	_	20	VMOD	_	_
23	.	_	.	_	_	13	P	_	_
		
1	They	_	PRP	_	_	2	VMOD	_	_
2	are	_	VBP	_	_	0	ROOT	_	_
3	also	_	RB	_	_	2	VMOD	_	_
4	known	_	VBN	_	_	2	VC	_	_
5	to	_	TO	_	_	4	VMOD	_	_
6	trigger	_	VB	_	_	5	IM	_	_
7	free	_	JJ	_	_	9	NMOD	_	_
8	radical	_	NN	_	_	9	NMOD	_	_
9	generation	_	NN	_	_	6	VMOD	_	_
10	.	_	.	_	_	2	P	_	_
		
1	The	_	DT	_	_	3	NMOD	_	_
2	present	_	JJ	_	_	3	NMOD	_	_
3	study	_	NN	_	_	4	VMOD	_	_
4	evaluated	_	VBD	_	_	0	ROOT	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	effect	_	NN	_	_	4	VMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	cumene	_	JJ	_	_	9	NMOD	_	_
9	hydroperoxide	_	NN	_	_	7	PMOD	_	_
10	(	_	(	_	_	11	P	_	_
11	Cum-OOH	_	NN	_	_	9	PRN	_	_
12	)	_	)	_	_	11	P	_	_
13	on	_	IN	_	_	6	NMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	induction	_	NN	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	activator	_	NN	_	_	18	NMOD	_	_
18	protein-1	_	NN	_	_	16	PMOD	_	_
19	(	_	(	_	_	20	P	_	_
20	AP-1	_	NN	_	_	18	PRN	_	_
21	)	_	)	_	_	20	P	_	_
22	,	_	,	_	_	18	P	_	_
23	which	_	WDT	_	_	24	VMOD	_	_
24	is	_	VBZ	_	_	18	NMOD	_	_
25	linked	_	VBN	_	_	24	VC	_	_
26	to	_	TO	_	_	25	VMOD	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	expression	_	NN	_	_	26	PMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	genes	_	NNS	_	_	29	PMOD	_	_
31	regulating	_	VBG	_	_	30	APPO	_	_
32	cell	_	NN	_	_	31	VMOD	_	_
33	proliferation	_	NN	_	_	32	NMOD	_	_
34	,	_	,	_	_	33	P	_	_
35	growth	_	NN	_	_	33	COORD	_	_
36	and	_	CC	_	_	35	COORD	_	_
37	transformation	_	NN	_	_	36	CONJ	_	_
38	.	_	.	_	_	4	P	_	_
		
1	Previously	_	RB	_	_	4	VMOD	_	_
2	,	_	,	_	_	4	P	_	_
3	we	_	PRP	_	_	4	VMOD	_	_
4	reported	_	VBD	_	_	0	ROOT	_	_
5	that	_	IN	_	_	4	VMOD	_	_
6	topical	_	JJ	_	_	7	NMOD	_	_
7	exposure	_	NN	_	_	10	VMOD	_	_
8	to	_	TO	_	_	7	NMOD	_	_
9	Cum-OOH	_	NN	_	_	8	PMOD	_	_
10	caused	_	VBD	_	_	5	SUB	_	_
11	formation	_	NN	_	_	10	VMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	free	_	JJ	_	_	14	NMOD	_	_
14	radicals	_	NNS	_	_	12	PMOD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	oxidative	_	JJ	_	_	17	NMOD	_	_
17	stress	_	NN	_	_	15	CONJ	_	_
18	in	_	IN	_	_	10	VMOD	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	skin	_	NN	_	_	18	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	vitamin	_	NN	_	_	24	NMOD	_	_
23	E-deficient	_	NN	_	_	24	NMOD	_	_
24	mice	_	NNS	_	_	21	PMOD	_	_
25	.	_	.	_	_	4	P	_	_
		
1	The	_	DT	_	_	3	NMOD	_	_
2	present	_	JJ	_	_	3	NMOD	_	_
3	study	_	NN	_	_	4	VMOD	_	_
4	used	_	VBD	_	_	0	ROOT	_	_
5	JB6	_	NN	_	_	9	NMOD	_	_
6	P+	_	NN	_	_	9	NMOD	_	_
7	mouse	_	NN	_	_	9	NMOD	_	_
8	epidermal	_	JJ	_	_	9	NMOD	_	_
9	cells	_	NNS	_	_	4	VMOD	_	_
10	and	_	CC	_	_	9	COORD	_	_
11	AP-1-luciferase	_	NN	_	_	14	NMOD	_	_
12	reporter	_	NN	_	_	14	NMOD	_	_
13	transgenic	_	JJ	_	_	14	NMOD	_	_
14	mice	_	NNS	_	_	10	CONJ	_	_
15	to	_	TO	_	_	4	VMOD	_	_
16	identify	_	VB	_	_	15	IM	_	_
17	whether	_	IN	_	_	16	VMOD	_	_
18	exposure	_	NN	_	_	21	VMOD	_	_
19	to	_	TO	_	_	18	NMOD	_	_
20	Cum-OOH	_	NN	_	_	19	PMOD	_	_
21	caused	_	VBD	_	_	17	SUB	_	_
22	activation	_	NN	_	_	21	VMOD	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	AP-1	_	NN	_	_	23	PMOD	_	_
25	,	_	,	_	_	22	P	_	_
26	oxidative	_	JJ	_	_	27	NMOD	_	_
27	stress	_	NN	_	_	22	COORD	_	_
28	,	_	,	_	_	27	P	_	_
29	depletion	_	NN	_	_	27	COORD	_	_
30	of	_	IN	_	_	29	NMOD	_	_
31	antioxidants	_	NNS	_	_	30	PMOD	_	_
32	and	_	CC	_	_	29	COORD	_	_
33	tumor	_	NN	_	_	34	NMOD	_	_
34	formation	_	NN	_	_	32	CONJ	_	_
35	during	_	IN	_	_	21	VMOD	_	_
36	two-stage	_	JJ	_	_	37	NMOD	_	_
37	carcinogenesis	_	NN	_	_	35	PMOD	_	_
38	.	_	.	_	_	4	P	_	_
		
1	In	_	FW	_	_	2	AMOD	_	_
2	vitro	_	FW	_	_	3	NMOD	_	_
3	studies	_	NNS	_	_	4	VMOD	_	_
4	found	_	VBD	_	_	0	ROOT	_	_
5	that	_	IN	_	_	4	VMOD	_	_
6	exposure	_	NN	_	_	9	VMOD	_	_
7	to	_	TO	_	_	6	NMOD	_	_
8	Cum-OOH	_	NN	_	_	7	PMOD	_	_
9	reduced	_	VBD	_	_	5	SUB	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	level	_	NN	_	_	9	VMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	glutathione	_	NN	_	_	12	PMOD	_	_
14	(	_	(	_	_	15	P	_	_
15	GSH	_	NN	_	_	13	PRN	_	_
16	)	_	)	_	_	15	P	_	_
17	in	_	IN	_	_	13	NMOD	_	_
18	mouse	_	NN	_	_	20	NMOD	_	_
19	epidermal	_	JJ	_	_	20	NMOD	_	_
20	cells	_	NNS	_	_	17	PMOD	_	_
21	(	_	(	_	_	23	P	_	_
22	JB6	_	NN	_	_	23	NMOD	_	_
23	P+	_	NN	_	_	20	PRN	_	_
24	)	_	)	_	_	23	P	_	_
25	and	_	CC	_	_	9	COORD	_	_
26	caused	_	VBD	_	_	25	CONJ	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	induction	_	NN	_	_	26	VMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	AP-1	_	NN	_	_	29	PMOD	_	_
31	.	_	.	_	_	4	P	_	_
		
1	Mice	_	NNS	_	_	8	VMOD	_	_
2	primed	_	VBN	_	_	1	APPO	_	_
3	with	_	IN	_	_	2	VMOD	_	_
4	dimethyl-benz[a]anthracene	_	NN	_	_	3	PMOD	_	_
5	(	_	(	_	_	6	P	_	_
6	DMBA	_	NN	_	_	4	PRN	_	_
7	)	_	)	_	_	6	P	_	_
8	were	_	VBD	_	_	0	ROOT	_	_
9	topically	_	RB	_	_	8	VMOD	_	_
10	exposed	_	VBN	_	_	8	VC	_	_
11	to	_	TO	_	_	10	VMOD	_	_
12	Cum-OOH	_	NN	_	_	11	PMOD	_	_
13	(	_	(	_	_	15	P	_	_
14	82.6	_	CD	_	_	15	NMOD	_	_
15	micromol	_	NN	_	_	12	PRN	_	_
16	)	_	)	_	_	15	P	_	_
17	or	_	CC	_	_	12	COORD	_	_
18	the	_	DT	_	_	20	NMOD	_	_
19	positive	_	JJ	_	_	20	NMOD	_	_
20	control	_	NN	_	_	17	CONJ	_	_
21	,	_	,	_	_	20	P	_	_
22	12-O-tetradecanoylphorbol-13-acetate	_	NN	_	_	20	APPO	_	_
23	(	_	(	_	_	24	P	_	_
24	TPA	_	NN	_	_	22	PRN	_	_
25	,	_	,	_	_	24	P	_	_
26	17	_	CD	_	_	27	NMOD	_	_
27	nmol	_	NN	_	_	24	APPO	_	_
28	)	_	)	_	_	24	P	_	_
29	,	_	,	_	_	20	P	_	_
30	twice	_	RB	_	_	32	PMOD	_	_
31	weekly	_	RB	_	_	30	AMOD	_	_
32	for	_	IN	_	_	10	VMOD	_	_
33	29	_	CD	_	_	34	NMOD	_	_
34	weeks	_	NNS	_	_	32	PMOD	_	_
35	.	_	.	_	_	8	P	_	_
		
1	Activation	_	NN	_	_	6	VMOD	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	AP-1	_	NN	_	_	2	PMOD	_	_
4	in	_	IN	_	_	1	NMOD	_	_
5	skin	_	NN	_	_	4	PMOD	_	_
6	was	_	VBD	_	_	0	ROOT	_	_
7	detected	_	VBN	_	_	6	VC	_	_
8	as	_	RB	_	_	7	VMOD	_	_
9	early	_	RB	_	_	8	AMOD	_	_
10	as	_	IN	_	_	7	VMOD	_	_
11	2	_	CD	_	_	12	NMOD	_	_
12	weeks	_	NNS	_	_	10	PMOD	_	_
13	following	_	VBG	_	_	7	VMOD	_	_
14	Cum-OOH	_	NN	_	_	13	PMOD	_	_
15	or	_	CC	_	_	14	COORD	_	_
16	TPA	_	NN	_	_	15	CONJ	_	_
17	exposure	_	NN	_	_	16	COORD	_	_
18	.	_	.	_	_	6	P	_	_
		
1	No	_	DT	_	_	3	NMOD	_	_
2	AP-1	_	NN	_	_	3	NMOD	_	_
3	expression	_	NN	_	_	4	VMOD	_	_
4	was	_	VBD	_	_	0	ROOT	_	_
5	found	_	VBN	_	_	4	VC	_	_
6	19	_	CD	_	_	7	NMOD	_	_
7	weeks	_	NNS	_	_	8	PMOD	_	_
8	after	_	IN	_	_	5	VMOD	_	_
9	initiation	_	NN	_	_	8	PMOD	_	_
10	.	_	.	_	_	4	P	_	_
		
1	Papilloma	_	NN	_	_	2	NMOD	_	_
2	formation	_	NN	_	_	3	VMOD	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	observed	_	VBN	_	_	3	VC	_	_
5	in	_	IN	_	_	4	VMOD	_	_
6	both	_	CC	_	_	11	DEP	_	_
7	the	_	DT	_	_	11	NMOD	_	_
8	DMBA-TPA-	_	JJ	_	_	11	NMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	DMBA-Cum-OOH-exposed	_	JJ	_	_	9	CONJ	_	_
11	animals	_	NNS	_	_	5	PMOD	_	_
12	,	_	,	_	_	3	P	_	_
13	whereas	_	IN	_	_	3	COORD	_	_
14	skin	_	NN	_	_	15	NMOD	_	_
15	carcinomas	_	NNS	_	_	16	VMOD	_	_
16	were	_	VBD	_	_	13	COORD	_	_
17	found	_	VBN	_	_	16	VC	_	_
18	only	_	RB	_	_	17	VMOD	_	_
19	in	_	IN	_	_	17	VMOD	_	_
20	the	_	DT	_	_	22	NMOD	_	_
21	DMBA-Cum-OOH-treated	_	JJ	_	_	22	NMOD	_	_
22	mice	_	NNS	_	_	19	PMOD	_	_
23	.	_	.	_	_	3	P	_	_
		
1	A	_	DT	_	_	3	NMOD	_	_
2	greater	_	JJR	_	_	3	NMOD	_	_
3	accumulation	_	NN	_	_	23	VMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	peroxidative	_	JJ	_	_	6	NMOD	_	_
6	products	_	NNS	_	_	4	PMOD	_	_
7	(	_	(	_	_	10	P	_	_
8	thiobarbituric	_	JJ	_	_	10	NMOD	_	_
9	acid-reactive	_	JJ	_	_	10	NMOD	_	_
10	substances	_	NNS	_	_	6	PRN	_	_
11	)	_	)	_	_	10	P	_	_
12	,	_	,	_	_	6	P	_	_
13	inflammation	_	NN	_	_	6	APPO	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	decreased	_	VBN	_	_	16	NMOD	_	_
16	levels	_	NNS	_	_	14	CONJ	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	GSH	_	NN	_	_	17	PMOD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	total	_	JJ	_	_	22	NMOD	_	_
21	antioxidant	_	JJ	_	_	22	NMOD	_	_
22	reserves	_	NNS	_	_	19	CONJ	_	_
23	were	_	VBD	_	_	0	ROOT	_	_
24	also	_	RB	_	_	23	VMOD	_	_
25	observed	_	VBN	_	_	23	VC	_	_
26	in	_	IN	_	_	25	VMOD	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	skin	_	NN	_	_	26	PMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	DMBA-Cum-OOH-exposed	_	JJ	_	_	31	NMOD	_	_
31	mice	_	NNS	_	_	29	PMOD	_	_
32	.	_	.	_	_	23	P	_	_
		
1	These	_	DT	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	3	VMOD	_	_
3	suggest	_	VBP	_	_	0	ROOT	_	_
4	that	_	IN	_	_	3	VMOD	_	_
5	Cum-OOH-induced	_	JJ	_	_	6	NMOD	_	_
6	carcinogenesis	_	NN	_	_	7	VMOD	_	_
7	is	_	VBZ	_	_	4	SUB	_	_
8	accompanied	_	VBN	_	_	7	VC	_	_
9	by	_	IN	_	_	8	VMOD	_	_
10	increased	_	VBN	_	_	12	NMOD	_	_
11	AP-1	_	NN	_	_	12	NMOD	_	_
12	activation	_	NN	_	_	9	PMOD	_	_
13	and	_	CC	_	_	12	COORD	_	_
14	changes	_	NNS	_	_	13	CONJ	_	_
15	in	_	IN	_	_	14	NMOD	_	_
16	antioxidant	_	JJ	_	_	17	NMOD	_	_
17	status	_	NN	_	_	15	PMOD	_	_
18	.	_	.	_	_	3	P	_	_
		
